Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Therapy for obesity based on gastrointestinal hormones

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. The Role of Iron in Type 1 Diabetes Etiology: A Systematic Review of New Evidence on a Long-Standing Mystery

    Research output: Contribution to journalReviewResearchpeer-review

  2. The alpha-cell as target for type 2 diabetes therapy

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Initiating or Switching to Biphasic Insulin Aspart 30/70 Therapy in Subjects with Type 2 Diabetes Mellitus. An Observational Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. VEuPathDB: the eukaryotic pathogen, vector and host bioinformatics resource center

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. The Glucagon Receptor Antagonist LY2409021 has No Effect on Postprandial Glucose in Type 2 Diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Vitamin D supplementation improves fasting insulin levels and HDL cholesterol in infertile men

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Effectiveness and acceptability of a pragmatic exercise intervention for patients with type 2 diabetes in specialized care

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
It has long been known that peptide hormones from the gastrointestinal tract have significant impact on the regulation of nutrient metabolism. Among these hormones, incretins have been found to increase insulin secretion, and thus incretin-based therapies have emerged as new modalities for the treatment of type 2 diabetes. In contrast to other antidiabetic treatments, these agents have a positive outcome profile on body weight. Worldwide there are 500 million obese people, and 3 million are dying every year from obesity-related diseases. Recently, incretin-based therapy was proposed for the treatment of obesity. Currently two different incretin therapies are widely used in the treatment of type 2 diabetes: 1) the GLP-1 receptor agonists which cause significant and sustained weight loss in overweight patients, and 2) dipeptidyl peptidase 4 (DPP-4) inhibitors being weight neutral. These findings have led to a greater interest in the physiology of intestinal peptides with potential weight-reducing properties. This review discusses the effects of the incretin-based therapies in obesity, and provides an overview of intestinal peptides with promising effects as potential new treatments for obesity.
Original languageEnglish
JournalReview of Diabetic Studies
Volume8
Issue number3
Pages (from-to)339-47
Number of pages9
ISSN1613-6071
DOIs
Publication statusPublished - 2011

ID: 33222808